EXAGEN INC. reported the three months ended March 31, 2026 results: revenue $17.3 million, net income Net loss $ (3,967). Guidance reaffirmed.
“Trailing-twelve-month average selling price (ASP) $ 444 $ 419 Cash and cash equivalents $ 21,513 $ 11,194 First Quarter 2026 Highlights: • Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025. • Grew AVISE CTD test volume 10% compared to first quarter 2025. • Expanded AVISE CTD trailing-twelve-month ASP to $444 per”
Kamal Adawi departed as Chief Financial Officer and Corporate Secretary at EXAGEN INC..
“replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of August 1, 2024.”
John Aballi was appointed as Interim Chief Financial Officer at EXAGEN INC..
“the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of August 1, 2024.”
Jeffrey Black was appointed as Chief Financial Officer at EXAGEN INC..
“On July 25, 2024, the Company appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.”
John Aballi was appointed as Interim Chief Financial Officer at EXAGEN INC..
“John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi”
Kamal Adawi departed as Chief Financial Officer and Corporate Secretary at EXAGEN INC..
“On July 31, 2024, the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of July 31, 2024.”
Jeffrey Black was appointed as Chief Financial Officer at EXAGEN INC..
“On July 25, 2024, Exagen Inc. (the “Company”) appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.”
Earnings Releases
EXAGEN INC. reported the quarter ended March 31, 2024 results: revenue $14.4 million, net income $3.4 million. Guidance raised.
“leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: • Recognized total revenue of $14.4 million in the first quarter of 2024, a 28.4% increase over the first quarter of 2023. • Delivered gross margin of 59.6% in the first quarter of 2024, compared to a gross margin of 47.2%”
Earnings Releases
EXAGEN INC. reported the quarter and year ended December 31, 2023 results: revenue $13.8 million for the fourth quarter of 2023, net income $5.6 million for the fourth quarter of 2023.
“On March 18, 2024 , the Company reported its financial results for the quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.